Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Champions Oncology, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 34 | 30 | −4 |
| Shares | 5.92M | 5.77M | −144.6K (−2.4%) |
| Value | $51.4M | $42.5M | −$8.82M (−17.2%) |
New holders (4)
Institutions that held Champions Oncology, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Dimensional Fund Advisors LP | 22,405 | $165.1K | 0.00% |
| XTX Topco Ltd | 14,034 | $103.4K | 0.00% |
| Gsa Capital Partners LLP | 10,415 | $77.0K | 0.01% |
| Lazard Asset Management LLC | 1,349 | $9.00K | 0.00% |
Sold out (8)
Institutions that held Champions Oncology, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| EAM Investors, LLC | 79,987 | $694.3K |
| Goldman Sachs Group Inc | 23,129 | $200.8K |
| Citadel Advisors LLC | 22,902 | $198.8K |
| Omers Administration Corp | 10,700 | $92.9K |
| Citigroup Inc | 4,915 | $42.7K |
| UBS Group AG | 529 | $4.59K |
| Tower Research Capital LLC (TRC) | 501 | $4.35K |
| Advisor Group Holdings, Inc. | 100 | $868 |